EP 1409540 A2 20040421 - MELANOCORTIN RECEPTOR LIGANDS
Title (en)
MELANOCORTIN RECEPTOR LIGANDS
Title (de)
MELANOCORTIN REZEPTOR LIGANDEN
Title (fr)
LIGANDS DE RECEPTEURS DE LA MELANOCORTINE
Publication
Application
Priority
- US 0130051 W 20010926
- US 23585800 P 20000927
Abstract (en)
[origin: WO0226774A2] Disclosed are MC-4 and/or MC-3 receptor ligands, the ligands having a structure according to Formula (I): wherein R<2>, R<4>, R<4'>, R<5>, R<6>, R<6'>, R<7>, R<8>, R<8'>, R<9>, R<9'>, R<10>, Ar, Z<1>, Z<2>, Z<3>, X, B, D, p, q, r and s are as described in the specification and claims, and optical isomers, diastereomers or enantiomers thereof; pharmaceutically-acceptable salts, hydrates, and biohydrolyzable esters, amides or imides thereof. Also disclosed are pharmaceutical compositions comprising the ligands of Formula (I), as well as methods of treating diseases mediate by the MC-4/MC-3 receptors, as described in the Detailed Descriptions section of the specification.
IPC 1-7
C07K 14/68; C07K 14/685; A61K 38/34; A61P 3/04; C07K 5/107; C07K 5/08; A61K 38/04; C07D 413/06; C07D 209/18; C07D 215/12; C07F 9/32; C07F 9/30; C07C 311/47
IPC 8 full level
A61K 38/06 (2006.01); A61K 38/07 (2006.01); A61K 38/34 (2006.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); A61P 3/10 (2006.01); A61P 7/02 (2006.01); A61P 9/10 (2006.01); A61P 9/12 (2006.01); A61P 11/04 (2006.01); A61P 15/00 (2006.01); A61P 19/02 (2006.01); A61P 19/06 (2006.01); A61K 38/00 (2006.01); A61P 25/18 (2006.01); A61P 35/00 (2006.01); C07K 5/00 (2006.01); C07K 5/02 (2006.01); C07K 5/065 (2006.01); C07K 5/072 (2006.01); C07K 5/078 (2006.01); C07K 5/08 (2006.01); C07K 5/087 (2006.01); C07K 5/10 (2006.01); C07K 5/103 (2006.01); C07K 5/107 (2006.01); C07K 5/117 (2006.01); C07K 5/12 (2006.01); C07K 14/68 (2006.01)
CPC (source: EP KR)
A61P 3/04 (2018.01 - EP); A61P 3/06 (2018.01 - EP); A61P 3/10 (2018.01 - EP); A61P 7/02 (2018.01 - EP); A61P 9/00 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 9/12 (2018.01 - EP); A61P 11/04 (2018.01 - EP); A61P 15/00 (2018.01 - EP); A61P 19/02 (2018.01 - EP); A61P 19/06 (2018.01 - EP); A61P 25/18 (2018.01 - EP); A61P 35/00 (2018.01 - EP); C07K 5/00 (2013.01 - KR); C07K 5/0207 (2013.01 - EP); C07K 5/06078 (2013.01 - EP); C07K 5/06095 (2013.01 - EP); C07K 5/06139 (2013.01 - EP); C07K 5/0812 (2013.01 - EP); C07K 5/0827 (2013.01 - EP); C07K 5/1008 (2013.01 - EP); C07K 5/1016 (2013.01 - EP); C07K 5/1024 (2013.01 - EP); C07K 5/1027 (2013.01 - EP); A61K 38/00 (2013.01 - EP)
Citation (examination)
- WO 9921571 A1 19990506 - TREGA BIOSCIENCES INC [US]
- HOLDER E.A., J.MED.CHEM., vol. 45, 2002, pages 2801 - 2810, XP001183565
- HOLDER E.A., ANN.N.Y.ACAD.SCI., vol. 994, 2003, pages 36 - 48, XP009037303
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0226774 A2 20020404; WO 0226774 A3 20030327; AR 030806 A1 20030903; AU 2001296313 B2 20050602; AU 9631301 A 20020408; BR 0114257 A 20030701; CA 2420045 A1 20020404; CN 1571796 A 20050126; CZ 2003788 A3 20030813; EP 1409540 A2 20040421; HU P0303085 A2 20031229; IL 154437 A0 20030917; JP 2004509974 A 20040402; KR 100519204 B1 20051006; KR 20030061814 A 20030722; MX PA03002691 A 20030606; NO 20031287 D0 20030320; NO 20031287 L 20030320; NZ 524190 A 20040924; PE 20020447 A1 20020702; PL 362003 A1 20041018; RU 2246501 C2 20050220; ZA 200301561 B 20040310
DOCDB simple family (application)
US 0130051 W 20010926; AR P010104557 A 20010927; AU 2001296313 A 20010926; AU 9631301 A 20010926; BR 0114257 A 20010926; CA 2420045 A 20010926; CN 01816384 A 20010926; CZ 2003788 A 20010926; EP 01977175 A 20010926; HU P0303085 A 20010926; IL 15443701 A 20010926; JP 2002531157 A 20010926; KR 20037004415 A 20030327; MX PA03002691 A 20010926; NO 20031287 A 20030320; NZ 52419001 A 20010926; PE 2001000965 A 20010927; PL 36200301 A 20010926; RU 2003112211 A 20010926; ZA 200301561 A 20030226